^
    Back
    Association details:
    Biomarker:RAD51D mutation
    Cancer:Breast Cancer
    Drug:Lynparza (olaparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.

    Excerpt:
    ...Cohort 1: Documented germline or somatic mutation in BRCA1, BRCA2, PALB2, RAD51C or RAD51D that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function)....
    Trial ID:
    RADIOLA
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2021
    Title:

    88P - Efficacy of olaparib in advanced cancers occurring in patients with germline or somatic tumor mutations in homologous recombination (HR) genes, a Belgian Precision phase II basket study

    Published date:
    09/13/2021
    Excerpt:
    Six partial responses occurred: a RAD51D breast cancer...Treatment with olaparib shows activity in cancer pts with a HR gene mutation and is well tolerated.
    Trial ID:
    1-2018 BSMO